M0324 + folinic acid + fluorouracil + irinotecan + oxaliplatin

A **combination regimen** containing M0324 (an investigational agent), folinic acid (leucovorin), fluorouracil (5-FU), irinotecan, and oxaliplatin. - **M0324** is a novel therapeutic currently being evaluated in early-phase trials, studied both as a monotherapy and in combination with pembrolizumab or chemotherapy in advanced solid tumors. The nature, modality, and exact mechanism of M0324 are not publicly detailed in the results; it is not yet described as a standard chemotherapeutic or targeted therapy[1][4]. - **Folinic acid** is a form of reduced folic acid that enhances the efficacy and tolerability of fluorouracil. - **Fluorouracil** (5-FU) is an antimetabolite that inhibits thymidylate synthase, disrupting DNA synthesis and inducing cytotoxicity, particularly in rapidly dividing tumor cells. - **Irinotecan** is a topoisomerase I inhibitor, causing single-strand breaks in DNA and leading to apoptosis in cancer cells. - **Oxaliplatin** forms DNA adducts and crosslinks, resulting in DNA damage and cell death; commonly used in gastrointestinal cancers. This regimen combines agents with complementary mechanisms for synergistic antitumor activity in solid tumors, with each drug having distinct action affecting DNA synthesis or repair.